Amid pressure from scientists, NIH will study Gilead’s remdesivir-like compound against Covid-19
The National Institutes of Health plans to independently explore whether a Gilead Sciences (GILD) compound, which some academics maintain is highly similar to remdesivir, but which the company has deemphasized in its efforts, may be useful in combating Covid-19.
The compound, called GS-441524, works in the same way as remdesivir to inhibit viruses, according to research that was conducted partly by the company. But the compound has not been tested in humans and, for the past few months, a pair of researchers at the University of Texas MD Anderson Cancer Center has argued publicly that Gilead ought to run tests.
